Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2026 | B-cell responses in recurrent respiratory papillomatosis treated with DNA immunotherapy INO-3107

Nabil Saba • 1 Jun 2026
ASCO 2026
Head and Neck Cancer Antibodies Bevacizumab INO-3107 MEDI0457 Zolbetuximab Zopapogene imadenovec

Nabil Saba, MD, Emory University, Atlanta, GA, discusses B-cell responses in patients with recurrent respiratory papillomatosis treated with DNA immunotherapy INO-3107. He highlights that this treatment induces specific B-cell responses in the blood and tissue, which correlate with clinical benefit, including reduced need for surgical resection. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Nabil Saba

ASCO guidelines update: systemic therapy sequencing in advanced thyroid cancer
3:09
ASCO guidelines update: systemic therapy sequencing in advanced thyroid cancer
Nabil Saba • 1 Jun 2026
NRG-HN015: Phase II trial of perioperative systemic therapy in recurrent head and neck cancer
3:11
NRG-HN015: Phase II trial of perioperative systemic therapy in recurrent head and neck cancer
Nabil Saba • 1 Jun 2026
INO-3107 and B-cell immunity: implications for HPV-associated cancers
1:29
INO-3107 and B-cell immunity: implications for HPV-associated cancers
Nabil Saba • 1 Jun 2026
DNA immunotherapy (INO-3107) in HPV-6 & 11 recurrent respiratory papillomatosis: long-term efficacy
2:42
DNA immunotherapy (INO-3107) in HPV-6 & 11 recurrent respiratory papillomatosis: long-term efficacy
Nabil Saba • 20 Oct 2025

Related Videos

IMRT deintensification in early-stage oropharyngeal cancer: insights from the JCOG1208 trial
0:34
IMRT deintensification in early-stage oropharyngeal cancer: insights from the JCOG1208 trial
Satoaki Nakamura • 16 May 2026
Considerations for HPV status in the JCOG1208 trial of IMRT in early-stage oropharyngeal cancer
0:41
Considerations for HPV status in the JCOG1208 trial of IMRT in early-stage oropharyngeal cancer
Satoaki Nakamura • 16 May 2026
Can IMRT alone be used for higher-risk oropharyngeal cancer?
0:42
Can IMRT alone be used for higher-risk oropharyngeal cancer?
Satoaki Nakamura • 16 May 2026
Could cemiplimab replace HHI therapy in BCCHN?
0:36
Could cemiplimab replace HHI therapy in BCCHN?
Hannah Kenny • 30 May 2026
The content of VJOncology is intended for healthcare professionals